The phase II randomized trial of conventional versus hypofractionated proton radiotherapy investigated whether condensing treatment to 15 fractions would be safe based on evidence that breast cancer is more sensitive to higher dose fractions than surrounding normal tissues. In this touchONCOLOGY interview, we speak with Dr Robert Mutter (Mayo Clinic Rochester, MN, United States) provides an overview of this trial and the impact of the findings.
The abstract entitled ‘Phase II randomized trial of conventional versus hypofractionated post-mastectomy proton radiotherapy’ was presented at San Antonio Breast Cancer Symposium (SABCS), 06–10, December, 2022.
Questions:
- What was the reason for the hypothesis that condensing treatment to 15 fractions would be safe, as opposed to conventional fractionation? (0:15)
- What were the methodology and eligibility criteria of your study? (2:09)
- What were the findings in terms of disease control, tolerability and reconstruction outcomes? (03:34)
- What will be the impact of these findings on future clinical trial design? (4:42)
Disclosures: Robert Mutter has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Shanice Allen
Filmed as a highlight of SABCS 2022
Access more content on Breast Cancer
